CardioDx Raises $60M in Private Financing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CardioDx today announced it has closed on a $60 million equity round.

The Palo Alto, Calif.-based cardiovascular genomics testing firm said that the funding will be used to expand reimbursement coverage in the US for its Corad CAD, a gene expression test to determine which patients have or don't have coronary artery disease. The test was launched in June 2009 as a laboratory-developed test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.